Idiopathic hyperphosphatasia and TNFRSF11B mutations:: Relationships between phenotype and genotype

被引:89
作者
Chong, B
Hegde, M
Fawkner, M
Simonet, S
Cassinelli, H
Coker, M
Kanis, J
Seidel, J
Tau, C
Tüysüz, B
Yüksel, B
Love, D
Cundy, T
机构
[1] Univ Auckland, Fac Med & Hlth Sci, Dept Med, Auckland 1, New Zealand
[2] Auckland Hosp, Mol Genet Lab, LabPlus, Auckland, New Zealand
[3] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA
[4] Amgen Inc, Dept Metab Disorders, Thousand Oaks, CA 91320 USA
[5] Hosp Ninos Buenos Aires, Div Endocrinol, Buenos Aires, DF, Argentina
[6] Ege Univ, Dept Pediat, Izmir, Turkey
[7] Univ Sheffield, Ctr Metab Bone Dis, Sheffield, S Yorkshire, England
[8] Univ Jena, Klin Kinder & Jugendmed, Jena, Germany
[9] Hosp Pediat JP Garrahan, Buenos Aires, DF, Argentina
[10] Istanbul Univ, Cerrahpasa Med Fac, Dept Pediat, Istanbul, Turkey
[11] Univ Curkurova, Div Genet & Teratol, Adana, Turkey
[12] Univ Auckland, Sch Biol Sci, Auckland 1, New Zealand
关键词
idiopathic hyperphosphatasia; juvenile Paget's disease; osteoprotegerin; phenotype-genotype; genetic bone disease; TNFRSF11B gene;
D O I
10.1359/jbmr.2003.18.12.2095
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Idiopathic hyperphosphatasia (IH) is a rare high bone turnover congenital bone disease in which affected children are normal at birth but develop progressive long bone deformities, fractures, vertebral collapse, skull enlargement, and deafness. There is, however, considerable phenotypic variation from presentation in infancy with severe progressive deformity through to presentation in late childhood with minimal deformity. Two recent reports have linked idiopathic hyperphosphatasia with deletion of, or mutation in, the TNFRSF11B gene that encodes osteoprotegerin (OPG), an important paracrine modulator of RANKL-mediated bone resorption. Materials and Methods: We studied subjects with a clinical diagnosis of IH and unaffected family members from nine unrelated families. Clinical, biochemical, and radiographic data were collected, and genomic DNA examined for mutations in TNFRSF11B. The relationship between the mutations, their predicted effects on OPG function, and the phenotype were then examined. Results: Of the nine families studied, affected subjects from six were homozygous for novel mutations in TNFRSF11B. Their parents were heterozygous, consistent with autosomal recessive inheritance. Four of the six mutations occurred in the cysteine-rich ligand-binding domain and are predicted to disrupt binding of OPG to RANKL. Missense mutations in the cysteine residues, predicted to cause major disruption to the ligand-binding region, were associated with a severe phenotype (deformity developing before 18 months age and severe disability), as was a large deletion mutation. Non-cysteine missense mutations in the ligand-binding domain were associated with an intermediate phenotype (deformity recognized around the age of 5 years and an increased rate of long bone fracture). An insertion/deletion mutation at the C-terminal end of the protein was associated with the mildest phenotype. Conclusion: Mutations in TNFRSF11B account for the majority of, but not all, cases of IH, and there are distinct genotype-phenotype relationships.
引用
收藏
页码:2095 / 2104
页数:10
相关论文
共 35 条
[1]   CHRONIC IDIOPATHIC HYPERPHOSPHATASEMIA - CASE-REPORT [J].
ANTONIADES, K ;
KARAKASIS, D ;
KAPETANOS, G ;
LASARIDIS, N ;
TZAROU, V .
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTICS, 1993, 76 (02) :200-204
[2]   FRAGILE BONES AND MACROCRANIUM [J].
BAKWIN, H ;
EIGER, MS .
JOURNAL OF PEDIATRICS, 1956, 49 (05) :558-564
[3]   CRYSTAL-STRUCTURE OF THE SOLUBLE HUMAN 55 KD TNF RECEPTOR-HUMAN TNF-BETA COMPLEX - IMPLICATIONS FOR TNF RECEPTOR ACTIVATION [J].
BANNER, DW ;
DARCY, A ;
JANES, W ;
GENTZ, R ;
SCHOENFELD, HJ ;
BROGER, C ;
LOETSCHER, H ;
LESSLAUER, W .
CELL, 1993, 73 (03) :431-445
[4]   FAMILIAL IDIOPATHIC HYPERPHOSPHATASIA - STUDY OF 2 YOUNG SIBLINGS TREATED WITH PORCINE CALCITONIN [J].
BLANCO, O ;
STIVEL, M ;
MAUTALEN, C ;
SCHAJOWICZ, F .
JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME, 1977, 59 (04) :421-427
[5]   osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification [J].
Bucay, N ;
Sarosi, I ;
Dunstan, CR ;
Morony, S ;
Tarpley, J ;
Capparelli, C ;
Scully, S ;
Tan, HL ;
Xu, WL ;
Lacey, DL ;
Boyle, WJ ;
Simonet, WS .
GENES & DEVELOPMENT, 1998, 12 (09) :1260-1268
[6]   FAMILIAL IDIOPATHIC HYPERPHOSPHATASIA (FIH) - RESPONSE TO LONG-TERM TREATMENT WITH PAMIDRONATE (APD) [J].
CASSINELLI, HR ;
MAUTALEN, CA ;
HEINRICH, JJ ;
MIGLIETTA, A ;
BERGADA, C .
BONE AND MINERAL, 1992, 19 (02) :175-184
[7]   POSTPARTUM HYPERCALCEMIA IN HEREDITARY HYPERPHOSPHATASIA (JUVENILE PAGETS-DISEASE) [J].
CHOSICH, N ;
LONG, F ;
WONG, R ;
TOPLISS, DJ ;
STOCKIGT, JR .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 1991, 14 (07) :591-597
[8]   A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype [J].
Cundy, T ;
Hegde, M ;
Naot, D ;
Chong, B ;
King, A ;
Wallace, R ;
Love, DR ;
Seidel, J ;
Fawkner, M ;
Banovic, T ;
Callon, KE ;
Grey, AB ;
Reid, IR ;
Middleton-Hardie, CA ;
Cornish, J .
HUMAN MOLECULAR GENETICS, 2002, 11 (18) :2119-2127
[9]   A place on the map [J].
de Costa, C .
LANCET, 2001, 357 (9259) :878-879
[10]  
Demir E, 2000, J PEDIATR ENDOCR MET, V13, P217